Less than 20% of patients with T2D are able to reach the treatment targets proposed by the American Diabetes Association [5,6], although therapeutic advances in the last decade by GLP-1 receptor agonists, SGLT2 inhibitors, dual receptor agonists such as tirzepatide [7], as well as a triple combinatorial therapy [8] have begun to provide promising results. Here, GLP1R is linked to type 2 diabetes mellitus.